Pheochromocytomas/paragangliomas (PGLs) are rare tumors and mostly benign. We report on a 32-year-old woman with metastatic PGL who was first diagnosed with an abdominal PGL at the age of 12 years. She soon developed metastatic disease and received several treatments including external beam radiation and chemotherapy. When she was referred to our institution in 2014, her major complaint was a rapidly growing chest wall mass on the left side. The patient was imaged at our institution with 4 different PET radiopharmaceuticals.
. A 32-year-old woman with known metastatic paraganglioma (PGL). The patient was referred to our center for further evaluation with a rapidly growing chest mass on the left side. PET scans with 4 different radiopharmaceuticals were performed as well as contrast-enhanced CT. The CT images (E) showed a very large, well-vascularized soft tissue mass (arrows) after the space between the left seventh and eighth ribs, measuring 19 Â 7.5 Â 5.5 cm. 18 F-FDG (B), which is unspecific, 1 but currently the radiopharmaceutical of choice for metastatic PGL 2 due to its far superiority over 123 I-MIBG, 3 and supposed to be an indicator for tumor dedifferentiation, 4 showed an intense uptake in this lesion as well as in scattered bone lesions, multiple retroperitoneal lesions, and a large pelvic mass. 18 F-L-dihydroxyphenylalanine, which is a specific and also very established radiopharmaceutical in functional imaging of PGLs with a known good detection rate especially for sporadic metastatic compared with hereditary PGL, 5 showed the same distribution (C) as well as 68 Ga DOTATATE (A). This is a new investigational radiopharmaceutical in PGL imaging addressing predominantly somatostatin receptor 2, 6 which is known to be overexpressed in most PGLs. 7 68 Ga DOTATATE PET/CT has recently shown very impressive results in imaging of sympathetic and parasympathetic PGLs, [8] [9] [10] [11] especially in patients with metastatic disease and underlying succinate dehydrogenase subunit B mutation 12 as well as in patients with parasympathetic head and neck PGLs. 13, 14 Positivity on 68 Ga DOTATATE PET provides also useful information about the possibility for a future treatment with 177 Lu DOTATATE. 18 F-fluorodopamine, also a very specific and established radiopharmaceutical in PGL imaging addressing the catecholamine synthesis and storage pathways, 15 was almost negative for all lesions (D). The identical imaging signature of the chest wall mass and the other metastatic lesions in all 4 different functional imaging modalities made the chest wall mass very suggestive for being a PGL metastases. Because the patient became more and more symptomatic, she finally underwent surgical resection of the chest wall mass, which was histologically consistent with metastatic PGL and confirmed the imaging findings.
